Molecular targets in acute myelogenous leukemia.

Abstract excerpt

Acute myeloid leukemia (AML) remains the most common form of leukemia and the most common cause of leukemia death. Although conventional chemotherapy can cure between 25 and 45% of AML patients, most patients will either die of relapse or die from the complications associated with treatment. Thus, more specific and less toxic treatments for AML patients are needed. Recently, a small molecular inhibitor (STI571 or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Enzyme Inhibitors
• Share to BCR gene
• Share to Leukemia, Myeloid, Acute